Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Health
|
Advocating for amendments to the Controlled Drugs and Substances Act to allow for the regulated use of psychedelics in therapeutic settings. This includes lobbying for policy development to support clinical trials and research into the therapeutic potential of substances like psilocybin and MDMA for treating mental health disorders.
|
Legislative Proposal, Bill or Resolution
|
Health
|
Engaging with policymakers to improve mental health care policies, focusing on integrating innovative treatments, including psychedelic-assisted therapies, into the national mental health care framework. Emphasis on funding, access, and training programs for healthcare professionals.
|
Policies or Program, Grant, Contribution or Other Financial Benefit
|
LaRubie.com engages in advocacy and policy consultation for mental health and psychedelic research. We focus on advancing legislative and regulatory frameworks that support the responsible integration of psychedelics into mental health practices. Our activities include policy development, educational outreach, and strategic guidance to stakeholders within the mental health and psychedelic sectors.
Stephanie Ghio, President
Address:
3045 place guillemette
apt 137
Laval, QC H7P 5N9
Canada
Telephone number:
514-619-4965
LaRubie is not a subsidiary of any other parent companies.
LaRubie does not have any subsidiaries that could have a direct interest in the outcome of the undertaking